<DOC>
	<DOCNO>NCT00226122</DOCNO>
	<brief_summary>Monosymptomatic nocturnal enuresis , define involuntary loss urine night age voluntary bladder control attain background normal urinary tract function , rather common disease childhood estimate prevalence 5-10 % tha age 7 spontaneous remission rate 15 % per year . The present study consist two phase ; in-patient phase ambulatory phase . In in-patient phase examine regulation sodium circadian rhythm hormone affect regulation child enuresis nocturnal healthy child , well impact indomethacin renal water electrolyte excretion . In ambulatory phase examine efficacy safety treatment modality consist combination dDAVP indomethacin patient severe enuresis dDAVP monotherapy inadequate . A significant number child enuresis nocturnal polyuria respond treatment dDAVP . If combination treatment dDAVP indomethacin prove superior dDAVP alone regimen could readily use difficult cure case enuresis .</brief_summary>
	<brief_title>The Effect Indomethacin Monosymptomatic Enuresis Nocturnal</brief_title>
	<detailed_description>The `` in-patient '' phase comparative circadian study three group participant non-placebo control study renal effect indomethacin special reference renal handling sodium . The ambulatory phase design randomize double blind , crossover placebo control indomethacin study efficacy safety combination treatment indomethacin dDAVP . In-patient phase : Primary effect parameter diuresis , urinary osmolality , sodium excretion prior administration indomethacin . Secondary effect parameter follow : GFR , K+ excretion , creatinine excretion , urea excretion , well urinary concentration aquaporin 2 ( AQP2 ) , PGE2 , AVP , URO , Na-transporter protein , concentration renin , ANG II , ALDO , ANP , plasma , prior administration indomethacin . Ambulatory phase : Primary effect parameter number dry night achieve two treatment period . Secondary effect parameter nocturnal urine production , enuresis volume In-patient phase : Day-night ratio calculate parameter test . The circadian rhythm hormone blood pressure electrolyte excretion analyze use COSINOR analysis . The effect indomethacin parameter test compare basal measurement use student 's t-test , ANOVA repeat measurement non-parametric test . All statistical inference take place `` protocol population '' basis . Ambulatory phase : The efficacy combination treatment test placebo ( indomethacin ) help student 's t-test , x2 test non-parametric test . The result home recording compare two treatment period use non-parametric test . The effect parameter undergo statistical analysis number wet night , enuresis volume nocturnal urine production . The analysis basis intention treat population .</detailed_description>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Nocturnal Enuresis</mesh_term>
	<mesh_term>Indomethacin</mesh_term>
	<criteria>Monosymptomatic enuresis nocturnal At least 3 night enuresis per week Incomplete response dDAVP Daytime incontinence Urgency Frequency Other condition influence normal urine production</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Enuresis</keyword>
	<keyword>Nocturnal</keyword>
	<keyword>Monosymptomatic</keyword>
	<keyword>DDAVP</keyword>
	<keyword>Indomethacin</keyword>
	<keyword>Randomized</keyword>
</DOC>